Optimizing Erythropoietic Health to Prevent Age-Related Hematologic Decline

Abstract

Age-related hematologic decline, characterized chiefly by anemia and impaired erythropoietic function, is a prevalent yet often under-recognized contributor to morbidity in older adults. Optimizing erythropoietic health is essential for maintaining functional status, quality of life, and reducing adverse outcomes in this population. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management of age-related erythropoietic decline, integrating emerging therapies and expert guideline recommendations to inform clinical practice.

Introduction

Hematologic aging is a multifactorial process that affects red blood cell production and survival, leading to a spectrum of clinical manifestations from subclinical cytopenias to overt anemia. Given the increasing lifespan of the global population, clinicians are increasingly tasked with identifying, preventing, and treating age-associated hematologic decline. The focus on erythropoietic health not only aims to reduce symptomatic anemia but also to address its insidious effects on frailty, cognition, and cardiovascular morbidity. Understanding the mechanisms and clinical consequences of declining erythropoiesis in older adults is paramount for evidence-based intervention.

Epidemiology / Disease Burden

Anemia affects approximately 10–24% of community-dwelling adults over age 65, with prevalence rising to over 40% in institutionalized elderly. Age-related hematologic decline is independently associated with increased mortality, hospitalization, falls, and diminished physical performance. Notably, a substantial proportion of cases are classified as anemia of unknown etiology, underscoring diagnostic and therapeutic challenges. Epidemiological studies highlight the public health significance of optimizing erythropoietic health to mitigate healthcare burden and enhance longevity in aging societies.

Pathophysiology

The mechanisms underlying age-related erythropoietic decline are complex, involving intrinsic bone marrow changes, altered erythropoietin (EPO) production and responsiveness, chronic inflammation, and comorbidities affecting nutrient absorption. Hematopoietic stem cell (HSC) exhaustion, increased myeloid skewing, and impaired erythroid progenitor function contribute to reduced red cell output. Age-associated low-grade inflammation, termed "inflammaging," leads to hepcidin-mediated iron sequestration and blunted EPO signaling. Concurrent renal insufficiency and endocrine dysregulation further impair erythropoiesis, perpetuating a cycle of anemia and functional decline.

Risk Factors

Key risk factors include advancing age, chronic kidney disease, diabetes mellitus, malnutrition, chronic inflammatory states, polypharmacy, gastrointestinal malabsorption, and deficiencies of iron, vitamin B12, or folate. In addition, underlying clonal hematopoiesis and myelodysplastic syndromes become increasingly prevalent with age, contributing to refractory or unexplained cytopenias. Social determinants, such as limited access to nutrition and healthcare, also play a contributory role, emphasizing the need for comprehensive risk assessment in geriatric patients.

Clinical Features

Clinical manifestations range from asymptomatic laboratory findings to pronounced symptoms such as fatigue, pallor, dyspnea, cognitive impairment, and reduced exercise tolerance. In older adults, anemia is frequently multifactorial and may exacerbate coexisting conditions such as heart failure or chronic kidney disease. Subtle presentations are common, necessitating a high index of suspicion for early detection. Falls, frailty, and new-onset cognitive decline should prompt evaluation for underlying hematologic compromise.

Diagnosis

Diagnostic evaluation encompasses a comprehensive history, physical examination, and targeted laboratory investigations. Complete blood count with red cell indices, reticulocyte count, iron studies, vitamin B12 and folate levels, renal and liver function tests, inflammatory markers, and thyroid function tests are essential. Bone marrow evaluation may be indicated in refractory or unexplained cases. The diagnostic approach should differentiate among nutritional deficiencies, chronic disease anemia, renal anemia, and clonal hematopoiesis, guiding tailored management strategies.

Treatment & Management

Management strategies are etiology-specific and may include nutritional supplementation, management of chronic comorbidities, optimization of renal function, and judicious use of erythropoiesis-stimulating agents (ESAs). Iron supplementation, preferably intravenous in the presence of malabsorption or chronic inflammation, is effective for iron-deficiency states. Correction of vitamin B12 or folate deficiency is essential when indicated. For anemia of chronic disease or renal origin, ESAs may be considered, balancing benefits against potential thromboembolic risk. Multidisciplinary care and regular monitoring are critical for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent research has elucidated novel therapeutic targets in age-related hematologic decline, including hepcidin antagonists, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), and agents targeting clonal hematopoiesis. HIF-PHIs, such as roxadustat, stimulate endogenous EPO production and improve iron utilization, offering promise for anemia in chronic kidney disease and inflammation. Anti-inflammatory interventions and senolytic therapies are under investigation to mitigate bone marrow microenvironment dysfunction. Advances in genomics enable early detection of clonal hematopoiesis, informing risk stratification and surveillance.

Guideline Recommendations

Professional guidelines, including those from the American Society of Hematology and the National Institute for Health and Care Excellence, recommend a systematic approach to anemia in older adults, emphasizing identification and correction of reversible causes, appropriate use of ESAs, and individualized transfusion thresholds. Routine screening in high-risk populations, comprehensive nutritional assessment, and avoidance of unnecessary polypharmacy are highlighted. Shared decision-making, considering patient comorbidities, preferences, and functional goals, remains central to optimal care.

Conclusion

Optimizing erythropoietic health in the aging population is a multidimensional challenge with substantial clinical implications. Age-related hematologic decline is both common and consequential, necessitating vigilant assessment, mechanism-based management, and integration of emerging therapies. Clinicians should adopt a proactive, individualized approach, informed by current evidence and expert guidelines, to prevent and ameliorate anemia in older adults, thereby enhancing longevity and quality of life.